EMA Unveils Strategy to Improve Women's Health in Drug Development

The European Medicines Agency (EMA) has introduced a new regulatory roadmap with 10 priority actions aimed at enhancing the consideration of women's health in medicines development. This initiative seeks to address existing gaps in research and drug development, which have contributed to poorer health outcomes and unmet medical needs for women. The roadmap signifies a concerted effort to improve equity in healthcare.